KIT and thymic carcinoma: Expression of CD5 in at least 50% of tumor cells and/or CD117 in at least 10% of tumor cells occurred in 10 (of 34, 29.4%) and 28 (of 35, 80%) thymic carcinomas, respectively, and in none of the thymomas.